TrialThe oncologist2016

Benefit-Risk Summary of Crizotinib for the Treatment of Patients With ROS1 Alteration-Positive, Metastatic Non-Small Cell Lung Cancer.

Dickran Kazandjian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.